Robert Flisiak

21.6k total citations · 2 hit papers
364 papers, 7.8k citations indexed

About

Robert Flisiak is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Robert Flisiak has authored 364 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 232 papers in Hepatology, 230 papers in Epidemiology and 69 papers in Infectious Diseases. Recurrent topics in Robert Flisiak's work include Hepatitis C virus research (193 papers), Liver Disease Diagnosis and Treatment (171 papers) and Hepatitis B Virus Studies (144 papers). Robert Flisiak is often cited by papers focused on Hepatitis C virus research (193 papers), Liver Disease Diagnosis and Treatment (171 papers) and Hepatitis B Virus Studies (144 papers). Robert Flisiak collaborates with scholars based in Poland, United States and Germany. Robert Flisiak's co-authors include Jerzy Jaroszewicz, Patrick Marcellin, D Prokopowicz, Anna Parfieniuk‐Kowerda, Edward Gane, Thomas Berg, Dorota Zarębska‐Michaluk, Michael Fried, Teerha Piratvisuth and Małgorzata Pawłowska and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Robert Flisiak

332 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

2005 1.1k citations Robert Flisiak et al. profile →
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

2014 592 citations Robert Flisiak et al. profile →

Peers

Countries citing papers authored by Robert Flisiak

Since Specialization

Citations

This map shows the geographic impact of Robert Flisiak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Flisiak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Flisiak more than expected).

Fields of papers citing papers by Robert Flisiak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Flisiak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Flisiak. The network helps show where Robert Flisiak may publish in the future.

Co-authorship network of co-authors of Robert Flisiak

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Flisiak. A scholar is included among the top collaborators of Robert Flisiak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Flisiak. Robert Flisiak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The burden of viral hepatitis infection and mortality: Findings from a population-based study in Poland over 2009–2023 2025 ·Clinical and Experimental Hepatology ·(unknown), Dorota Zarębska‐Michaluk, (unknown), Piotr Tyszko, Birutė Strukčinskienė, Iwona Paradowska‐Stankiewicz, Piotr Rzymski, Robert Flisiak	0
2	RSV prevention in adults: consensus of experts of Polish scientific societies 2025 ·Family Medicine & Primary Care Review ·Adam Antczak, Adam Barczyk, (unknown), (unknown), Robert Flisiak, Robert Gil, Marcin Grabowski, Aleksander Kania, (unknown), Rafał Krenke, Ernest Kuchar, Artur Mamcarz, Aneta Nitsch‐Osuch, Iwona Paradowska‐Stankiewicz, Jacek Wysocki, Krzysztof Tomasiewicz	0
3	Hepatic involvement in major respiratory viral infections 2025 ·Clinical and Experimental Hepatology ·Piotr Rzymski, (unknown), (unknown), Dorota Zarębska‐Michaluk, Robert Flisiak	0
4	Steatotic liver disease in patients treated for chronic hepatitis B 2025 ·Polskie Archiwum Medycyny Wewnętrznej ·(unknown), (unknown), (unknown), Robert Flisiak, (unknown), (unknown), Robert Pleśniak, (unknown), (unknown), Dorota Zarębska‐Michaluk	3
5	Seroprevalence of RSV IgG Antibodies Across Age Groups in Poland After the COVID-19 Pandemic: Data from the 2023/2024 Epidemic Season 2025 ·Vaccines ·Barbara Poniedziałek, (unknown), (unknown), Aleksander Masny, Anna Poznańska, Karol Szymański, (unknown), (unknown), (unknown), Lidia B. Brydak, Krzysztof Tomasiewicz, Robert Flisiak, Piotr Rzymski	2
6	Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Consequences and Anti-Inflammatory Treatment 2024 ·Medical Science Monitor ·Kacper Toczyłowski, (unknown), (unknown), Anna Moniuszko‐Malinowska, (unknown), Anna Parfieniuk‐Kowerda, Robert Flisiak, Artur Sulik	2
7	Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices 2024 ·Pharmacological Reports ·(unknown), Dorota Zarębska‐Michaluk, Michał Kukla, (unknown), Dorota Dybowska, Ewa Janczewska, Beata Lorenc, Hanna Berak, Włodzimierz Mazur, Magdalena Tudrujek‐Zdunek, (unknown), Anna Piekarska, (unknown), (unknown), Anna Parfieniuk‐Kowerda, Robert Flisiak	1
8	Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide 2024 ·Clinical and Experimental Hepatology ·(unknown), Anna Piekarska, Hanna Berak, Włodzimierz Mazur, Aleksander Garlicki, Magdalena Tudrujek‐Zdunek, Beata Lorenc, Dorota Dybowska, (unknown), Anna Parfieniuk‐Kowerda, Robert Flisiak	0
9	Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study 2024 ·Viruses ·(unknown), Jerzy Jaroszewicz, Dorota Zarębska‐Michaluk, Magdalena Rogalska, Piotr Czupryna, Marta Rorat, Dorota Kozielewicz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Beata Bolewska, Regina Podlasin, Robert Flisiak	2
10	Cannabinoids and the endocannabinoid system in liver diseases 2024 ·Clinical and Experimental Hepatology ·Anna Parfieniuk‐Kowerda, (unknown), (unknown), (unknown), Robert Flisiak	0
11	Treatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population 2024 ·Polskie Archiwum Medycyny Wewnętrznej ·Robert Flisiak, Dorota Zarębska‐Michaluk, Hanna Berak, Magdalena Tudrujek‐Zdunek, Beata Lorenc, (unknown), (unknown), Włodzimierz Mazur, Anna Parfieniuk‐Kowerda, Jerzy Jaroszewicz	2
12	Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination 2024 ·BMC Medicine ·Dorota Zarębska‐Michaluk, (unknown), Olga Tronina, (unknown), (unknown), Anna Piekarska, (unknown), Anna Parfieniuk‐Kowerda, (unknown), Magdalena Tudrujek‐Zdunek, (unknown), Robert Flisiak	1
13	Impact of the COVID-19 and War Migration on HIV/AIDS Epidemiology in Poland 2024 ·Journal of Clinical Medicine ·(unknown), Dorota Zarębska‐Michaluk, Miłosz Parczewski, Birutė Strukčinskienė, Piotr Rzymski, Robert Flisiak	1
14	Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure 2023 ·Clinical and Experimental Hepatology ·Olga Tronina, (unknown), Dorota Zarębska‐Michaluk, Beata Lorenc, (unknown), Hanna Berak, (unknown), Dorota Dybowska, Włodzimierz Mazur, Magdalena Tudrujek‐Zdunek, Ewa Janczewska, (unknown), (unknown), Anna Parfieniuk‐Kowerda, (unknown), (unknown), Robert Flisiak	1
15	Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals 2023 ·Clinical and Experimental Hepatology ·Robert Flisiak, Dorota Zarębska‐Michaluk, Hanna Berak, Dorota Dybowska, (unknown), Anna Parfieniuk‐Kowerda, (unknown), Ewa Janczewska, Anna Piekarska, Beata Lorenc, Włodzimierz Mazur, (unknown), Magdalena Tudrujek‐Zdunek, (unknown), Jerzy Jaroszewicz	4
16	Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens 2023 ·Viruses ·Olga Tronina, (unknown), Dorota Zarębska‐Michaluk, Dorota Dybowska, Beata Lorenc, Ewa Janczewska, Włodzimierz Mazur, Anna Parfieniuk‐Kowerda, Anna Piekarska, (unknown), (unknown), Hanna Berak, Jerzy Jaroszewicz, Aleksander Garlicki, Krzysztof Tomasiewicz, (unknown), Robert Flisiak	3
17	Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland 2023 ·Journal of Clinical Medicine ·(unknown), Dorota Zarębska‐Michaluk, Birutė Strukčinskienė, Artūras Razbadauskas, Anna Moniuszko‐Malinowska, Jonas Jurgaitis, Robert Flisiak	11
18	The Role of Th17 Response in COVID-19 2021 ·Cells ·(unknown), Anna Parfieniuk‐Kowerda, Magdalena Rogalska, Robert Flisiak	91
19	Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries 2020 ·Journal of Hepatology ·Pietro Lampertico, Robert Flisiak, Nuno Marques, Olivier Clerc, Ioannis Goulis, (unknown), Ariel Porcalla, Zhenzhen Zhang, Yves Horsmans, Harald Hofer, Ella Veitsman, Georges‐Philippe Pageaux	2
20	New therapeutic options for HCV in Central Europe 2016 ·Clinical and Experimental Hepatology ·Robert Flisiak, Petr Urbánek, (unknown), Marián Oltman, Mihály Makara, Martin Janíčko	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact